Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Features
AMS Features
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Systemic ketoconazole continues to be prescribed despite an FDA warning
By
Aesthetic Multispecialty Society
posted
Oct 20, 2020 08:45 AM
0
Recommend
.
0 comments
0 views
Related Content
Thread Lifting in 2022: The Evolution Continues
Informa Admin
Added Nov 30, 2022
Blog Entry
FDA Strengthens Safety Requirements and Updates Study Results for Breast Implants
Aesthetic Multispecialty Society
Added Nov 10, 2021
Blog Entry
U.S. FDA Approves New MENTOR MemoryGel BOOST Breast Implant
Aesthetic Multispecialty Society
Added Jan 21, 2022
Blog Entry
Galderma Receives FDA Approval for New Sculptra Label, Offering More Options to Aesthetic Partners
Aesthetic Multispecialty Society
Added Jan 19, 2022
Blog Entry
FDA Warns on Use of Certain Surgical Mesh in Breasxt Reconstruction
Aesthetic Multispecialty Society
Added May 18, 2021
Blog Entry
Permalink
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic